Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of WRSs2 Vaccine Against Shigella Sonnei
NCT04242264Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WRSs2 in shigellosis, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2022; status: completed.
02
Drugs
WRSs2
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT04242264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242264.